Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer

* Patients will receive Iressa and anastrozole orally once daily until treatment is ended. Treatment will end if any of the following occur: Unacceptable adverse effects; bowel obstruction; initiation of systemic chemotherapy; development of new ascites or pleural effusions, development of co-morbid disease or disease progression. * Patients will be given a drug log in which to record the date and time they take their pills, as well as any symptoms and concomitant medications. * Patients will be seen monthly for the following tests and procedures; a physical examination and repeat blood work. Patients who remain free of clinical symptoms should have repeat abdominal/pelvic CT scans and chest x-rays on an every 3 month basis.